A Closer Look At Topical Therapies In Wound Care
- Volume 26 - Issue 8 - August 2013
- 7912 reads
- 0 comments
29. Gordon J. Clinical significance of MRSA in UK hospitals and the relevance of povidone-iodine in their control. Postgrad Med J. 1993; 69(Suppl 3):106-16.
30. Mertz PM, Alvarez O, Smerbeck RV, Eaglstein WH. A new in vivo model for the evaluation of topical antiseptics on superficial wounds: the effect of 70% alcohol and povidone-iodine. Arch Dermatol. 1984; 120(1):58-62.
31. Gomez JH, Schumacher J, Lauten SD, Sartin EA, Hathcock TL, Swaim SF. Effects of 3 biologics dressings on healing cutaneous wounds on the limbs of horses. Can J Vet Res. 2004; 68(1):49-55.
32. Ramanujam CL, Zgonis T. An overview of autologous skin grafts and advanced biologics for the diabetic foot. Clin Podiatr Med Surg. 2012; 29(3):435-441.
33. Mostow EN, Haraway GD, Dalsing M, et al. Oasis venous ulcer study group. Effectiveness of an extracellular matrix graft (OASIS Wound Matrix) in the treatment of chronic leg ulcers: a randomized clinical trial. J Vasc Surg. 2005; 41(5):837-43.
34. Veves A. Falanga V, Armstrong DG, et al. Apligraf diabetic foot ulcer study. Graftskin, a human skin equivalent, is effective in the management of noninfected neuropathic diabetic foot ulcers: a prospective randomized multicenter clinic trial. Diabetes Care. 2001; 24(2):290-5.
35. Kirsner R, Warriner R, Michaela M, Stasik L, Freeman K. Advanced biological therapies for diabetic foot ulcers. Arch Dermatol. 2010; 146(8):857-862.
36. O’Donnell E. Epifix human amniotic membrane allograft use in the treatment of chronic diabetic wounds. Clinical Symposium on Advances in Skin and Wound Care. Kissimmee, Fla. September 29, 2010-October 2, 2010.
For further reading, see “A Comprehensive Review Of Topical Agents” in the July 2012 issue of Podiatry Today.